FUELCELL ENERGY INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that FUELCELL ENERGY INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Oct 31, 2018 | $17.88M | Jan 10, 2019 |
| FY2018 | Jul 31, 2018 | $12.11M | Jan 10, 2019 |
| FY2018 | Apr 30, 2018 | $20.83M | Jan 10, 2019 |
| FY2018 | Jan 31, 2018 | $38.61M | Jan 10, 2019 |
| FY2018 | Oct 31, 2017 | $47.89M | Jan 10, 2019 |
| FY2018 | Jul 31, 2017 | $10.36M | Jan 10, 2019 |
| FY2018 | Apr 30, 2017 | $20.42M | Jan 10, 2019 |
| FY2018 | Jan 31, 2017 | $17.00M | Jan 10, 2019 |
| FY2017 | Oct 31, 2016 | $24.47M | Jan 11, 2018 |
| FY2017 | Jul 31, 2016 | $21.72M | Jan 11, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $158.16M | Dec 18, 2025 |
| FY2025 | Oct 31, 2024 | $112.13M | Dec 18, 2025 |
| FY2025 | Oct 31, 2023 | $123.39M | Dec 18, 2025 |
| FY2024 | Oct 31, 2022 | $130.48M | Dec 27, 2024 |
| FY2023 | Oct 31, 2021 | $69.59M | Dec 19, 2023 |
| FY2020 | Oct 31, 2020 | $17.00M | Jan 21, 2021 |
| FY2020 | Jul 31, 2020 | $18.73M | Jan 21, 2021 |
| FY2020 | Apr 30, 2020 | $18.88M | Jan 21, 2021 |
| FY2020 | Jan 31, 2020 | $16.26M | Jan 21, 2021 |
| FY2020 | Oct 31, 2019 | $11.04M | Jan 21, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Oct 31, 2020 | ($8.05M) | Jan 21, 2021 |
| FY2020 | Jul 31, 2020 | ($3.13M) | Jan 21, 2021 |
| FY2020 | Apr 30, 2020 | $167.0K | Jan 21, 2021 |
| FY2020 | Jan 31, 2020 | $3.28M | Jan 21, 2021 |
| FY2020 | Oct 31, 2019 | ($23.39M) | Jan 21, 2021 |
| FY2020 | Jul 31, 2019 | $7.97M | Jan 21, 2021 |
| FY2020 | Apr 30, 2019 | ($3.64M) | Jan 21, 2021 |
| FY2020 | Jan 31, 2019 | ($2.21M) | Jan 21, 2021 |
| FY2019 | Oct 31, 2018 | $1.14M | Jan 22, 2020 |
| FY2019 | Jul 31, 2018 | ($2.06M) | Jan 22, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | ($187.90M) | Dec 18, 2025 |
| FY2025 | Oct 31, 2024 | ($126.01M) | Dec 18, 2025 |
| FY2025 | Oct 31, 2023 | ($107.57M) | Dec 18, 2025 |
| FY2024 | Oct 31, 2022 | ($142.72M) | Dec 27, 2024 |
| FY2023 | Oct 31, 2021 | ($101.06M) | Dec 19, 2023 |
| FY2020 | Oct 31, 2020 | ($18.86M) | Jan 21, 2021 |
| FY2020 | Jul 31, 2020 | ($15.33M) | Jan 21, 2021 |
| FY2020 | Apr 30, 2020 | ($14.77M) | Jan 21, 2021 |
| FY2020 | Jan 31, 2020 | ($40.15M) | Jan 21, 2021 |
| FY2020 | Oct 31, 2019 | ($35.18M) | Jan 21, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | ($192.35M) | Dec 18, 2025 |
| FY2025 | Oct 31, 2024 | ($158.49M) | Dec 18, 2025 |
| FY2025 | Oct 31, 2023 | ($136.08M) | Dec 18, 2025 |
| FY2024 | Oct 31, 2022 | ($143.72M) | Dec 27, 2024 |
| FY2023 | Oct 31, 2021 | ($64.90M) | Dec 19, 2023 |
| FY2020 | Oct 31, 2020 | ($17.12M) | Jan 21, 2021 |
| FY2020 | Jul 31, 2020 | ($10.76M) | Jan 21, 2021 |
| FY2020 | Apr 30, 2020 | ($8.14M) | Jan 21, 2021 |
| FY2020 | Jan 31, 2020 | ($3.14M) | Jan 21, 2021 |
| FY2020 | Oct 31, 2019 | ($32.99M) | Jan 21, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $34.08M | Dec 18, 2025 |
| FY2025 | Oct 31, 2024 | $55.40M | Dec 18, 2025 |
| FY2025 | Oct 31, 2023 | $61.02M | Dec 18, 2025 |
| FY2024 | Oct 31, 2022 | $34.53M | Dec 27, 2024 |
| FY2023 | Oct 31, 2021 | $11.32M | Dec 19, 2023 |
| FY2022 | Oct 31, 2020 | $4.80M | Dec 20, 2022 |
| FY2021 | Oct 31, 2019 | $13.79M | Dec 29, 2021 |
| FY2020 | Oct 31, 2018 | $22.82M | Jan 21, 2021 |
| FY2019 | Oct 31, 2017 | $20.40M | Jan 22, 2020 |
| FY2018 | Oct 31, 2016 | $20.85M | Jan 10, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $60.74M | Dec 18, 2025 |
| FY2025 | Oct 31, 2024 | $64.60M | Dec 18, 2025 |
| FY2025 | Oct 31, 2023 | $64.53M | Dec 18, 2025 |
| FY2024 | Oct 31, 2022 | $79.62M | Dec 27, 2024 |
| FY2023 | Oct 31, 2021 | $37.95M | Dec 19, 2023 |
| FY2022 | Oct 31, 2020 | $26.64M | Dec 20, 2022 |
| FY2021 | Oct 31, 2019 | $31.87M | Dec 29, 2021 |
| FY2020 | Oct 31, 2018 | $24.91M | Jan 21, 2021 |
| FY2019 | Oct 31, 2017 | $25.92M | Jan 22, 2020 |
| FY2018 | Oct 31, 2016 | $25.15M | Jan 10, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | ($125.29M) | Dec 18, 2025 |
| FY2025 | Oct 31, 2024 | ($152.91M) | Dec 18, 2025 |
| FY2025 | Oct 31, 2023 | ($140.25M) | Dec 18, 2025 |
| FY2024 | Oct 31, 2022 | ($112.17M) | Dec 27, 2024 |
| FY2023 | Oct 31, 2021 | ($70.44M) | Dec 19, 2023 |
| FY2022 | Oct 31, 2020 | ($36.78M) | Dec 20, 2022 |
| FY2021 | Oct 31, 2019 | ($30.57M) | Dec 29, 2021 |
| FY2020 | Oct 31, 2018 | $16.32M | Jan 21, 2021 |
| FY2019 | Oct 31, 2017 | ($71.85M) | Jan 22, 2020 |
| FY2018 | Oct 31, 2016 | ($46.60M) | Jan 10, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $932.15M | Dec 18, 2025 |
| FY2025 | Oct 31, 2024 | $944.12M | Dec 18, 2025 |
| FY2024 | Oct 31, 2023 | $955.52M | Dec 27, 2024 |
| FY2023 | Oct 31, 2022 | $939.72M | Dec 19, 2023 |
| FY2022 | Oct 31, 2021 | $875.25M | Dec 20, 2022 |
| FY2021 | Oct 31, 2020 | $523.54M | Dec 29, 2021 |
| FY2020 | Oct 31, 2019 | $333.45M | Jan 21, 2021 |
| FY2019 | Oct 31, 2018 | $340.42M | Jan 22, 2020 |
| FY2018 | Oct 31, 2017 | $383.79M | Jan 10, 2019 |
| FY2017 | Oct 31, 2016 | $340.73M | Jan 11, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $201.01M | Dec 18, 2025 |
| FY2025 | Oct 31, 2024 | $216.66M | Dec 18, 2025 |
| FY2024 | Oct 31, 2023 | $195.22M | Dec 27, 2024 |
| FY2023 | Oct 31, 2022 | $185.33M | Dec 19, 2023 |
| FY2022 | Oct 31, 2021 | $169.92M | Dec 20, 2022 |
| FY2021 | Oct 31, 2020 | $269.13M | Dec 29, 2021 |
| FY2020 | Oct 31, 2019 | $197.85M | Jan 21, 2021 |
| FY2019 | Oct 31, 2018 | $163.50M | Jan 22, 2020 |
| FY2018 | Oct 31, 2017 | $194.97M | Jan 10, 2019 |
| FY2017 | Oct 31, 2016 | $166.48M | Jan 11, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $662.18M | Dec 18, 2025 |
| FY2025 | Oct 31, 2024 | $656.92M | Dec 18, 2025 |
| FY2024 | Oct 31, 2023 | $682.49M | Dec 27, 2024 |
| FY2023 | Oct 31, 2022 | $684.39M | Dec 19, 2023 |
| FY2022 | Oct 31, 2021 | $642.44M | Dec 20, 2022 |
| FY2021 | Oct 31, 2020 | $194.55M | Dec 29, 2021 |
| FY2020 | Oct 31, 2019 | $75.74M | Jan 21, 2021 |
| FY2020 | Oct 31, 2018 | $82.19M | Jan 21, 2021 |
| FY2020 | Oct 31, 2017 | $101.26M | Jan 21, 2021 |
| FY2019 | Oct 31, 2016 | $114.40M | Jan 22, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2024 | $4.08M | Dec 18, 2025 |
| FY2024 | Oct 31, 2023 | $4.08M | Dec 27, 2024 |
| FY2023 | Oct 31, 2022 | $4.08M | Dec 19, 2023 |
| FY2022 | Oct 31, 2021 | $4.08M | Dec 20, 2022 |
| FY2021 | Oct 31, 2020 | $4.08M | Dec 29, 2021 |
| FY2020 | Oct 31, 2019 | $4.08M | Jan 21, 2021 |
| FY2019 | Oct 31, 2018 | $4.08M | Jan 22, 2020 |
| FY2018 | Oct 31, 2017 | $4.08M | Jan 10, 2019 |
| FY2017 | Oct 31, 2016 | $4.08M | Jan 11, 2018 |
| FY2016 | Oct 31, 2015 | $4.08M | Jan 12, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | ($1.83B) | Dec 18, 2025 |
| FY2025 | Oct 31, 2024 | ($1.64B) | Dec 18, 2025 |
| FY2024 | Oct 31, 2023 | ($1.52B) | Dec 27, 2024 |
| FY2023 | Oct 31, 2022 | ($1.41B) | Dec 19, 2023 |
| FY2022 | Oct 31, 2021 | ($1.27B) | Dec 20, 2022 |
| FY2021 | Oct 31, 2020 | ($1.16B) | Dec 29, 2021 |
| FY2021 | Nov 1, 2019 | $0 | Dec 29, 2021 |
| FY2020 | Oct 31, 2019 | ($1.08B) | Jan 21, 2021 |
| FY2019 | Oct 31, 2018 | ($990.87M) | Jan 22, 2020 |
| FY2018 | Oct 31, 2017 | ($943.53M) | Jan 10, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $278.10M | Dec 18, 2025 |
| FY2025 | Oct 31, 2024 | $148.13M | Dec 18, 2025 |
| FY2025 | Oct 31, 2023 | $249.95M | Dec 18, 2025 |
| FY2024 | Oct 31, 2022 | $458.06M | Dec 27, 2024 |
| FY2022 | Oct 31, 2021 | $432.21M | Dec 20, 2022 |
| FY2021 | Oct 31, 2020 | $149.87M | Dec 29, 2021 |
| FY2020 | Oct 31, 2019 | $9.43M | Jan 21, 2021 |
| FY2019 | Oct 31, 2018 | $39.29M | Jan 22, 2020 |
| FY2018 | Oct 31, 2017 | $49.29M | Jan 10, 2019 |
| FY2017 | Oct 31, 2016 | $84.19M | Jan 11, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Oct 31, 2014 | $10.75M | Jan 9, 2015 |
| FY2014 | Oct 31, 2013 | $50.88M | Jan 9, 2015 |
| FY2013 | Oct 31, 2012 | $8.55M | Jan 6, 2014 |
| FY2012 | Oct 31, 2011 | $8.68M | Jan 15, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | (7) | Dec 18, 2025 |
| FY2025 | Oct 31, 2024 | (7) | Dec 18, 2025 |
| FY2025 | Oct 31, 2023 | (7) | Dec 18, 2025 |
| FY2024 | Oct 31, 2022 | (11) | Dec 27, 2024 |
| FY2023 | Oct 31, 2021 | 0 | Dec 19, 2023 |
| FY2022 | Oct 31, 2020 | 0 | Dec 20, 2022 |
| FY2021 | Oct 31, 2019 | (1) | Dec 29, 2021 |
| FY2020 | Oct 31, 2018 | (9) | Jan 21, 2021 |
| FY2019 | Oct 31, 2017 | (13) | Jan 22, 2020 |
| FY2018 | Oct 31, 2016 | (1) | Jan 10, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | (7) | Dec 18, 2025 |
| FY2025 | Oct 31, 2024 | (7) | Dec 18, 2025 |
| FY2025 | Oct 31, 2023 | (7) | Dec 18, 2025 |
| FY2024 | Oct 31, 2022 | (11) | Dec 27, 2024 |
| FY2023 | Oct 31, 2021 | 0 | Dec 19, 2023 |
| FY2022 | Oct 31, 2020 | 0 | Dec 20, 2022 |
| FY2021 | Oct 31, 2019 | (1) | Dec 29, 2021 |
| FY2020 | Oct 31, 2018 | (9) | Jan 21, 2021 |
| FY2019 | Oct 31, 2017 | (13) | Jan 22, 2020 |
| FY2018 | Oct 31, 2016 | (1) | Jan 10, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | 46.08M | Dec 18, 2025 |
| FY2025 | Nov 8, 2024 | 20.38M | Dec 18, 2025 |
| FY2025 | Nov 7, 2024 | 611.28M | Dec 18, 2025 |
| FY2025 | Oct 31, 2024 | 20.38M | Dec 18, 2025 |
| FY2024 | Oct 31, 2023 | 15.02M | Dec 27, 2024 |
| FY2023 | Oct 31, 2022 | 405.56M | Dec 19, 2023 |
| FY2022 | Oct 31, 2021 | 366.62M | Dec 20, 2022 |
| FY2021 | Oct 31, 2020 | 294.71M | Dec 29, 2021 |
| FY2020 | Oct 31, 2019 | 193.61M | Jan 21, 2021 |
| FY2021 | May 8, 2019 | 15.28M | Dec 29, 2021 |